DAPT score: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
==DAPT Score== | ==DAPT Score== | ||
The DAPT score is a risk score derived from the DAPT ([[Dual antiplatelet therapy|Dual Antiplatelet Therapy]]) Trial. It is a validated risk assessment tool designed to assess the risk-benefit of the [[dual antiplatelet therapy]] following [[PCI]] and insertion of a drug-eluting [[stent]].<ref name="YehSecemsky2016">{{cite journal|last1=Yeh|first1=Robert W.|last2=Secemsky|first2=Eric A.|last3=Kereiakes|first3=Dean J.|last4=Normand|first4=Sharon-Lise T.|last5=Gershlick|first5=Anthony H.|last6=Cohen|first6=David J.|last7=Spertus|first7=John A.|last8=Steg|first8=Philippe Gabriel|last9=Cutlip|first9=Donald E.|last10=Rinaldi|first10=Michael J.|last11=Camenzind|first11=Edoardo|last12=Wijns|first12=William|last13=Apruzzese|first13=Patricia K.|last14=Song|first14=Yang|last15=Massaro|first15=Joseph M.|last16=Mauri|first16=Laura|title=Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention|journal=JAMA|volume=315|issue=16|year=2016|pages=1735|issn=0098-7484|doi=10.1001/jama.2016.3775}}</ref> | The DAPT score is a risk score derived from the DAPT ([[Dual antiplatelet therapy|Dual Antiplatelet Therapy]]) Trial. It is a validated risk assessment tool designed to assess the risk-benefit of the [[dual antiplatelet therapy]] following [[PCI]] and insertion of a drug-eluting [[stent]].<ref name="YehSecemsky2016">{{cite journal|last1=Yeh|first1=Robert W.|last2=Secemsky|first2=Eric A.|last3=Kereiakes|first3=Dean J.|last4=Normand|first4=Sharon-Lise T.|last5=Gershlick|first5=Anthony H.|last6=Cohen|first6=David J.|last7=Spertus|first7=John A.|last8=Steg|first8=Philippe Gabriel|last9=Cutlip|first9=Donald E.|last10=Rinaldi|first10=Michael J.|last11=Camenzind|first11=Edoardo|last12=Wijns|first12=William|last13=Apruzzese|first13=Patricia K.|last14=Song|first14=Yang|last15=Massaro|first15=Joseph M.|last16=Mauri|first16=Laura|title=Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention|journal=JAMA|volume=315|issue=16|year=2016|pages=1735|issn=0098-7484|doi=10.1001/jama.2016.3775}}</ref><ref name="PiccoloGargiulo2017">{{cite journal|last1=Piccolo|first1=Raffaele|last2=Gargiulo|first2=Giuseppe|last3=Franzone|first3=Anna|last4=Santucci|first4=Andrea|last5=Ariotti|first5=Sara|last6=Baldo|first6=Andrea|last7=Tumscitz|first7=Carlo|last8=Moschovitis|first8=Aris|last9=Windecker|first9=Stephan|last10=Valgimigli|first10=Marco|title=Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention|journal=Annals of Internal Medicine|volume=167|issue=1|year=2017|pages=17|issn=0003-4819|doi=10.7326/M16-2389}}</ref><ref name="KereiakesYeh2016">{{cite journal|last1=Kereiakes|first1=Dean J.|last2=Yeh|first2=Robert W.|last3=Massaro|first3=Joseph M.|last4=Cutlip|first4=Donald E.|last5=Steg|first5=P. Gabriel|last6=Wiviott|first6=Stephen D.|last7=Mauri|first7=Laura|title=DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction|journal=Journal of the American College of Cardiology|volume=67|issue=21|year=2016|pages=2492–2502|issn=07351097|doi=10.1016/j.jacc.2016.03.485}}</ref><ref name="YoshikawaShiomi2018">{{cite journal|last1=Yoshikawa|first1=Yusuke|last2=Shiomi|first2=Hiroki|last3=Watanabe|first3=Hirotoshi|last4=Natsuaki|first4=Masahiro|last5=Kondo|first5=Hirokazu|last6=Tamura|first6=Toshihiro|last7=Nakagawa|first7=Yoshihisa|last8=Morimoto|first8=Takeshi|last9=Kimura|first9=Takeshi|title=Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies|journal=Circulation|volume=137|issue=6|year=2018|pages=551–562|issn=0009-7322|doi=10.1161/CIRCULATIONAHA.117.028924}}</ref><ref name="BanerjeeAngiolillo2017">{{cite journal|last1=Banerjee|first1=Subhash|last2=Angiolillo|first2=Dominick J.|last3=Boden|first3=William E.|last4=Murphy|first4=Joseph G.|last5=Khalili|first5=Houman|last6=Hasan|first6=Ahmed A.|last7=Harrington|first7=Robert A.|last8=Rao|first8=Sunil V.|title=Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery|journal=Journal of the American College of Cardiology|volume=69|issue=14|year=2017|pages=1861–1870|issn=07351097|doi=10.1016/j.jacc.2017.02.012}}</ref><ref>{{cite journal|title=An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction|journal=New England Journal of Medicine|volume=329|issue=10|year=1993|pages=673–682|issn=0028-4793|doi=10.1056/NEJM199309023291001}}</ref> | ||
==DAPT Score Calculator== | ==DAPT Score Calculator== | ||
Revision as of 02:43, 1 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Synonyms and keywords: Dual Antiplatelet Therapy score
Overview
The DAPT score is a risk score derived from the DAPT (Dual Antiplatelet Therapy) Trial. It is a validated risk assessment tool designed to assess the risk-benefit of the dual antiplatelet therapy following PCI and insertion of a drug-eluting stent.
DAPT Score
The DAPT score is a risk score derived from the DAPT (Dual Antiplatelet Therapy) Trial. It is a validated risk assessment tool designed to assess the risk-benefit of the dual antiplatelet therapy following PCI and insertion of a drug-eluting stent.[1][2][3][4][5][6]
DAPT Score Calculator
Shown below is the calculator for DAPT score (check all the boxes that apply):
Interpretation
- Score <2: Higher risk of bleeding and a smaller reduction in ischemia, associated with an unfavorable benefit-to-risk ratio for prolonged DAPT
- Score ≥2: Smaller risk of bleeding and a greater reduction in ischemia, associated with a favorable benefit-to-risk ratio for prolonged DAPT
See also
References
- ↑ Yeh, Robert W.; Secemsky, Eric A.; Kereiakes, Dean J.; Normand, Sharon-Lise T.; Gershlick, Anthony H.; Cohen, David J.; Spertus, John A.; Steg, Philippe Gabriel; Cutlip, Donald E.; Rinaldi, Michael J.; Camenzind, Edoardo; Wijns, William; Apruzzese, Patricia K.; Song, Yang; Massaro, Joseph M.; Mauri, Laura (2016). "Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention". JAMA. 315 (16): 1735. doi:10.1001/jama.2016.3775. ISSN 0098-7484.
- ↑ Piccolo, Raffaele; Gargiulo, Giuseppe; Franzone, Anna; Santucci, Andrea; Ariotti, Sara; Baldo, Andrea; Tumscitz, Carlo; Moschovitis, Aris; Windecker, Stephan; Valgimigli, Marco (2017). "Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention". Annals of Internal Medicine. 167 (1): 17. doi:10.7326/M16-2389. ISSN 0003-4819.
- ↑ Kereiakes, Dean J.; Yeh, Robert W.; Massaro, Joseph M.; Cutlip, Donald E.; Steg, P. Gabriel; Wiviott, Stephen D.; Mauri, Laura (2016). "DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction". Journal of the American College of Cardiology. 67 (21): 2492–2502. doi:10.1016/j.jacc.2016.03.485. ISSN 0735-1097.
- ↑ Yoshikawa, Yusuke; Shiomi, Hiroki; Watanabe, Hirotoshi; Natsuaki, Masahiro; Kondo, Hirokazu; Tamura, Toshihiro; Nakagawa, Yoshihisa; Morimoto, Takeshi; Kimura, Takeshi (2018). "Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies". Circulation. 137 (6): 551–562. doi:10.1161/CIRCULATIONAHA.117.028924. ISSN 0009-7322.
- ↑ Banerjee, Subhash; Angiolillo, Dominick J.; Boden, William E.; Murphy, Joseph G.; Khalili, Houman; Hasan, Ahmed A.; Harrington, Robert A.; Rao, Sunil V. (2017). "Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery". Journal of the American College of Cardiology. 69 (14): 1861–1870. doi:10.1016/j.jacc.2017.02.012. ISSN 0735-1097.
- ↑ "An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction". New England Journal of Medicine. 329 (10): 673–682. 1993. doi:10.1056/NEJM199309023291001. ISSN 0028-4793.